Hormone refractory prostate cancer: Management and advances

Related Experiment Video

Updated: Aug 11, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Guru Sonpavde1, Thomas E Hutson, William R Berry

  • 1US Oncology Research Network Houston, TX, USA. guru.sonpavde@usoncology.com

Cancer Treatment Reviews
|February 7, 2006
PubMed

Insights

New chemotherapy options offer hope for advanced prostate cancer. Combining docetaxel with novel biologic agents shows promise for improving long-term outcomes in patients resistant to hormone therapy.

Area of Science:

  • Oncology
  • Medical Science

Background:

  • Prostate cancer progression after androgen deprivation therapy (ADT) has limited effective treatment options.
  • Previous secondary hormonal manipulations provided only marginal benefits for patients with advanced prostate cancer.

Purpose of the Study:

  • To review the recent advancements in therapeutic options for prostate cancer progressing after ADT.
  • To highlight the potential of combining docetaxel chemotherapy with novel biologic agents.

Main Methods:

  • Review of two large randomized trials demonstrating the efficacy of docetaxel-based chemotherapy.
  • Discussion of emerging novel biologic agents including vaccines, monoclonal antibodies, and targeted therapies.

Main Results:

  • Docetaxel-based chemotherapy has shown to extend survival and alter the natural history of advanced prostate cancer.
  • The combination of docetaxel with novel agents is being explored to enhance long-term patient outcomes.

Conclusions:

  • The future of prostate cancer treatment is promising with the development of new therapeutic strategies.
  • Combining established chemotherapy with innovative biologic agents offers a new frontier for managing treatment-resistant prostate cancer.

More Related Videos

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance05:19

A New Technique for Treating Low-risk Prostate Cancer—Super Active Surveillance

Published on: November 7, 2025

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra. Symptoms...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...